Louisiana State Employees Retirement System Grows Stake in Repligen Co. (NASDAQ:RGEN)

Louisiana State Employees Retirement System boosted its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 0.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,500 shares of the biotechnology company’s stock after buying an additional 100 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Repligen were worth $2,087,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of RGEN. CWM LLC grew its holdings in Repligen by 36.3% during the third quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 114 shares during the period. Creative Planning grew its stake in shares of Repligen by 32.6% during the 3rd quarter. Creative Planning now owns 5,123 shares of the biotechnology company’s stock valued at $762,000 after acquiring an additional 1,259 shares during the period. NBC Securities Inc. increased its holdings in Repligen by 92.2% in the 3rd quarter. NBC Securities Inc. now owns 2,931 shares of the biotechnology company’s stock worth $436,000 after acquiring an additional 1,406 shares in the last quarter. nVerses Capital LLC bought a new stake in Repligen during the 3rd quarter worth approximately $45,000. Finally, Trust Point Inc. lifted its holdings in Repligen by 4.8% during the third quarter. Trust Point Inc. now owns 7,893 shares of the biotechnology company’s stock valued at $1,175,000 after purchasing an additional 359 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on RGEN shares. Wolfe Research assumed coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. Canaccord Genuity Group began coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. TD Cowen started coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective for the company. Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Finally, StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Six equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and a consensus price target of $186.00.

Repligen Trading Up 0.5 %

RGEN stock opened at $146.92 on Friday. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13. The stock has a market capitalization of $8.23 billion, a price-to-earnings ratio of -397.07, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The firm’s fifty day simple moving average is $155.42 and its two-hundred day simple moving average is $149.16.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same period in the prior year, the firm posted $0.23 EPS. The firm’s revenue was up 9.7% compared to the same quarter last year. As a group, analysts anticipate that Repligen Co. will post 1.54 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.